Clinical Trials
4
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Utility of the Blood-Based Proteomic Integrated Classifier and Auto-Antibody Tests in the Real-World
- Conditions
- Lung Nodules
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Biodesix, Inc.
- Target Recruit Count
- 4000
- Registration Number
- NCT06728319
- Locations
- 🇺🇸
Pulmonary & Sleep of Tampa Bay, Brandon, Florida, United States
🇺🇸White-Wilson Medical Center, Fort Walton Beach, Florida, United States
🇺🇸Southcoast Health System, Fairhaven, Massachusetts, United States
Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules
- Conditions
- Nodule Solitary PulmonaryNon-small Cell Carcinoma
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Biodesix, Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT04171492
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital, Boston, Connecticut, United States
🇺🇸Beth Israel Deaconess, Boston, Connecticut, United States
A Registry to Evaluate the Performance of the BDX-XL2 Test
- Conditions
- Nodule Solitary PulmonaryNSCLC
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Biodesix, Inc.
- Target Recruit Count
- 842
- Registration Number
- NCT03766958
- Locations
- 🇺🇸
Banner Health, Sun City, Arizona, United States
🇺🇸Amicis Research Center, Northridge, California, United States
🇺🇸Pueblo Pulmonary Associates, Pueblo, Colorado, United States
Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
- Conditions
- Non-Small Cell Lung Cancer
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Biodesix, Inc.
- Target Recruit Count
- 5006
- Registration Number
- NCT03289780
- Locations
- 🇺🇸
Oncology Specialties, PC; Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Lewis & Faye Manderson Cancer Center at DCH Regional Medical Center, Tuscaloosa, Alabama, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
News
Oncimmune Enters Administration After Failed Sale Attempts and Funding Shortfall
Precision medicine company Oncimmune Holdings has entered administration after failing to secure a buyer for its German subsidiary or raise additional capital to meet short-term funding needs.